Diagnosis. Forty percent of new patients have normal erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) 7, 8 , and > 30% test negative for rheumatoid factor or anti-citrullinated protein antibodies (ACPA) 9 .
Management. Clinical decisions in RA are based more on a patient history and physical examination than on biomarkers; in contrast, biomarkers dominate clinical decisions in many chronic diseases, and may include vital signs (e.g., blood pressure in hypertension); laboratory tests (e.g., hemoglobin A1c in diabetes); imaging (e.g., computed tomographic scan in pulmonary fibrosis), or other ancillary studies (e.g., endoscopy in inflammatory bowel disease) 10 .
Prognosis. The most significant markers for future quality of life and premature mortality in RA are not laboratory tests, radiographs, indices, or remission criteria, but individual patient self-report measures of patient global estimate of status or physical function 11 .
In the absence of a single gold standard biomarker (or any measure) applicable to each individual patient with RA 12 , pooled indices 13 are needed to assess and monitor clinical status quantitatively, and to provide quantitative remission criteria. These indices are based on a core data set for RA 14 of 7 measures: 3 from patient self-report, 3 from physical examination, but only 1 laboratory test -ESR or CRP -reflecting limitations of biomarkers and the promin-ence of patient history and physical examination in RA 10 . Remission according to Disease Activity Score with 28 joint count (DAS28) 15 , Simplified Disease Activity Index (SDAI) 16 , Clinical Disease Activity Index (CDAI) 16 , and Routine Assessment of Patient Index Data (RAPID3) 17 has been described. More recently, more stringent "Boolean" criteria, as well as SDAI score ≤ 3.3, have been advocated by a committee of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 18, 19 .
The highest levels of remission reported in RA are seen in clinical trials of a treat-to-target strategy 20, 21, 22, 23, 24, 25 (Table 1) . However, in most series from usual clinical care, only 6-33% of patients met even the least stringent DAS28 remission criteria 17, 26, 27, 28, 29, 30, 31, 32 (Table 1) . Therefore, an important, if not critical, task for the rheumatology community is to document effective rheumatology care although only a minority of patients reach the stated goal of clinical remission. This goal might be met more effectively by analyzing efforts to control the most significant individual core data set measures to achieve improved quality of life and reversal of premature mortality -patient global estimate and physical function on a patient questionnaire -rather than by focusing on indices or remission.
A report by Linde, et al 33 in this issue of The Journal documents the value of a patient global estimate of status to explain improvement in quality of life associated with treatment of RA. Among the 4 measures of the DAS28, swollen and tender joint counts were less significant, CRP was not at all significant, while patient global estimate was most significant to explain improvement in quality of life during treatment with biological therapies. Their report extends impressive contributions from the Danish community to international rheumatology, including much information about biological therapies in usual care from the comprehensive DANBIO registry 34 , and the Ciclosporine, Methotrexate, Steroid in RA (CIMESTRA) trial 24 21 Tight Control for Rheumatoid Arthritis (TICORA) trial; 65% intensive group; DAS; single-blind RCT 16% usual care group; DAS Verstappen, 2007 22 Computer Assisted Management in Early Rheumatoid Arthritis 50% intensive group; Utrecht criteria*; (CAMERA) study; open-label strategy trial 37% conventional group Utrecht criteria* Klarenbeek, 2011 23 BehandelStrategien (BeSt) or "treatment strategies" trial 23% drug-free remission Hetland, 2012 24 Ciclosporine, Methotrexate, Steroid in RA (CIMESTRA) 56%; Boolean; 78%; DAS28 Wevers-de Boer, 2012 25 Induction 
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A measure of quality of life is a criterion used by insurance companies and government payers to estimate the potential value of biological therapies for a patient with RA. Control of patient global estimate, rather than joint counts, radiographic scores, or laboratory tests, could be more valuable to justify expensive RA treatments. Remission might become a valuable surrogate in the future if it was commonly achieved, say, in two-thirds of patients in usual care, rather than in one-third (the maximum reported rate today).
Another important possible target for control using an individual RA patient questionnaire measure involves physical function and longterm mortality. The natural history of RA involves the shortening of lifespan by about a decade, comparable to hypertension and diabetes 35, 36 . Further, diseases such as systemic lupus erythematosus (SLE) 37 , polymyositis 38 , vasculitis, and systemic sclerosis are associated with increased mortality rates, comparable to or greater than most forms of cardiovascular and neoplastic diseases 39, 40 . RA and other inflammatory rheumatic diseases should be monitored routinely for 5-year survival and other mortality outcomes, as is the case for cardiovascular and neoplastic diseases.
In RA, the most significant predictor of mortality is a patient questionnaire measure of physical function -not a laboratory test or other biomarker -documented initially almost 30 years ago 35, 41 , confirmed in a second cohort observed from 1985-1990 42 , and in 15 of 16 reported RA cohorts 43 (Figure 1 ). Further, a measure of physical function on a patient questionnaire is more significant than any laboratory test or radiographic score to predict costs, work disability, or even joint replacement surgery 11 . The only outcome predicted most significantly by radiographs or laboratory tests is radiographic progression 44 , which appears less relevant to the other longterm outcomes noted than patient questionnaire scores. Even if premature mortality is falling, the relative importance of physical function likely remains; in a study in Finland, physical function on Health Assessment Questionnaire (HAQ) predicted 5-year mortality at higher levels than smoking in 
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Possible documentation of control of physical function in RA to achieve a lower level might provide a marker for improved longterm outcomes, including improved survival. This would be analogous to documentation of improved survival based on control of blood pressure in hypertension 3, 4 , serum glucose in diabetes 5 , or serum cholesterol in hyperlipidemia 6 . Reduction of mortality may be regarded as a universal goal of all medical care, usually understood by payers for medical services more easily than any other outcome.
It appears likely that improved physical function would be associated with improved survival, based on pioneering studies of improved mortality outcomes associated with methotrexate treatment by Krause 46 and Choi 47 , as well as with biologic agents by Jacobsson 48 . Improvement in physical function scores with these agents is well established. However, it remains to be documented that improvement of HAQ or Multidimensional HAQ (MDHAQ) score in an individual patient will result directly in a significant change in mortality outcomes, analogous to studies in other chronic diseases 23, 24 .
Another difference between RA and other chronic diseases (in addition to the absence of a gold standard biomarker) is that RA is not associated with acute emergencies and sudden death, as may be seen in hypertension and diabetes. It might therefore be suggested that the absence of possible acute catastrophe in RA might limit support for aggressive treatment, based on control of physical function to improve survival. However, a major activity of contemporary clinical medicine involves treatment, with statins, of apparently normal, usually asymptomatic, individuals who have elevated serum cholesterol. The rationale is almost entirely based on epidemiologic data that control of serum cholesterol is associated with improved survival, rather than based on clinical signs or symptoms 6 ; although control of a biomarker is accepted more readily than a patient questionnaire score as an important measure by most physicians (including most rheumatologists).
Patient global estimate and physical function may be assessed easily on HAQ 49 or MDHAQ 50 , as 2 of the 7 RA core data set 14 measures. However, quantitative clinical data from a patient history in the form of a patient self-report questionnaire, and even from physical examination in the form of joint counts and physician global estimate, have not been incorporated by most clinical rheumatologists, at least in the United States 51 . Further, most training programs continue to neglect these quantitative clinical measures. Indeed, the only quantitative data in the medical records of most RA patients of most rheumatologists -even todayare laboratory tests, despite their limitations in clinical decision and prognosis. Therefore, current medical records of most rheumatologists could not be used to document improved clinical status for most patients with RA, or even remission; much less to achieve control of the most significant prognostic markers.
Completing the HAQ or MDHAQ creates no extra work for the doctor, nor interference with patient flow, when distributed by the receptionist in a cheerful manner to each patient at each visit and/or completed by patients electronically in the waiting area. An MDHAQ helps the patient prepare for the visit, improves doctor-patient communication, and saves time for the doctor, with a 10-15 second overview of information from a self-report joint count, review of systems, and recent medical history that would otherwise require 10-15 minutes of conversation to elicit 52 . Patient questionnaires do not prevent collection of any additional quantitative data such as joint counts, laboratory tests, or radiographic scores; however, longterm databases concerning RA patients, such as DANBIO 34 , are needed to document possible improvements in quality of life according to better control of patient global estimates, and possible improvements in longterm mortality according to better of physical function.
Most rheumatologists may do as much for their patients as other specialists, but rheumatology is underappreciated by the general medical community and the general public; not to mention under-reimbursed. Epidemiologic evidence of improved quality of life and survival after control of the patient global estimate and physical function could facilitate reimbursement by insurance and government payers.
If remission criteria were met by the majority of patients, support for expensive biological therapies in RA might be likely. However, because most people with RA are not in remission, other documentation of the value of treatment is needed. Patient global estimate and physical function are far more informative than laboratory tests, joint counts, radiographs, indices, or remission criteria to recognize improved RA outcomes. Routine collection of these quantitative data on patient questionnaires in the infrastructure of clinical care to document control to achieve more favorable values, rather than simple notation of gestalt impressions by the physician, would appear to be an intellectual and ethical responsibility to our patients with RA. 
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